Huang Xing, Hou Shengzhong, Li Yinggang, Xu Gang, Xia Ning, Duan Zhenyu, Luo Kui, Tian Bole
Division of Pancreatic Surgery, Department of General Surgery, Department of Radiology, Huaxi MR Research Center (HMRRC), Liver Transplant Center, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Division of Pancreatic Surgery, Department of General Surgery, Department of Radiology, Huaxi MR Research Center (HMRRC), Liver Transplant Center, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China; Functional and Molecular Imaging Key Laboratory of Sichuan Province, Key Laboratory of Transplant Engineering and Immunology, NHC, and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.
Biomaterials. 2025 Jun;317:123022. doi: 10.1016/j.biomaterials.2024.123022. Epub 2024 Dec 15.
Lipid metabolism has been increasingly recognized to play an influencing role in tumor initiation, progression, metastasis, and therapeutic drug resistance. Targeting lipid metabolic reprogramming represents a promising therapeutic strategy. Despite their structural complexity and poor targeting efficacy, lipid-metabolizing drugs, either used alone or in combination with chemotherapeutic agents, have been employed in clinical practice. The advent of nanotechnology offers new approaches to enhancing therapeutic effects, includingthe targeted delivery and integration of lipid metabolic reprogramming with chemotherapy, photodynamic therapy (PDT), and immunotherapy. The integrated nanoformulation, nanomedicine, could significantly advance the field of lipid metabolism therapy. In this review, we will briefly introduce the concept of cancer lipid metabolism reprogramming, then elaborate the latest advances in engineered nanomedicine for targeting lipid metabolism during cancer treatment, and finally provide our insights into future perspectives of nanomedicine for interference with lipid metabolism in the tumor microenvironment.
脂质代谢在肿瘤的起始、进展、转移和治疗耐药性中发挥的影响作用已得到越来越多的认可。靶向脂质代谢重编程是一种很有前景的治疗策略。尽管脂质代谢药物结构复杂且靶向效果不佳，但单独使用或与化疗药物联合使用的脂质代谢药物已应用于临床实践。纳米技术的出现为提高治疗效果提供了新方法，包括脂质代谢重编程与化疗、光动力疗法（PDT）和免疫疗法的靶向递送与整合。整合的纳米制剂，即纳米药物，可显著推动脂质代谢治疗领域的发展。在本综述中，我们将简要介绍癌症脂质代谢重编程的概念，然后阐述用于癌症治疗期间靶向脂质代谢的工程纳米药物的最新进展，最后就纳米药物干扰肿瘤微环境中脂质代谢的未来前景发表我们的见解。
